Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Underweight
- Symbol (ENDP)
- Company Endo International plc
- Price $0.29
- Changes Percentage (0%)
- Change -$0
- Day Low $0.28
- Day High $0.31
- Year High $0.31
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/09/2022
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $2.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.11
- Trailing P/E Ratio -0.09
- Forward P/E Ratio -0.09
- P/E Growth -0.09
- Net Income $-569,081,000
Income Statement
Quarterly
Annual
Latest News of ENDP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
J&J's Shockwave deal pays off as IVL catheter meets primary endpoint in trial
Johnson & Johnson's Javelin IVL catheter system by Shockwave Medical successfully met primary endpoints in a clinical trial for treating peripheral artery disease (PAD). The innovative system showed s...
By Yahoo! Finance | 1 week ago -
LENZ Therapeutics Shares Climb After Presbyopia Trial Hits Endpoints
LENZ Therapeutics' stock surged 13% in premarket trading after successful Phase 3 trial results for its presbyopia treatment in China. The study showed significant improvement in visual acuity, with p...
By MarketWatch | 3 weeks ago -
Alto Neuroscience Shares Plunge After ALTO-100 Study Misses Primary Endpoint
Alto Neuroscience's stock hit record lows in after-hours trading after its ALTO-100 Phase 2 study failed to meet the primary goal. Shares dropped 63% to $5.36, hitting an intraday low of $7.91 in Augu...
By MarketWatch | 3 weeks ago
